Abstract: The incidence of intraductal papillary mucinous neoplasms (IPMNs) has been increasing over the past decade, mainly owing to increased awareness and the increased use of cross-sectional imaging. The Sendai and Fukuoka consensus guidelines provide us with clinical management guidelines and algorithms; however, the clinical management of IPMNs continues to be challenging. Our incomplete understanding of the natural history of the disease, and the events and pathways that permit progression to adenocarcinoma, result in difficulties predicting which tumors are high risk and will progress to invasive disease. In this review, we summarize the current management guidelines and describe ongoing efforts to more clearly stratify IPMNs by risk of malignancy and identify IPMNs with malignant potential or ongoing malignant transformation.
I
ntraductal papillary mucinous neoplasms (IPMNs) were first described in 1982 by Ohhashi et al, 1 who described 4 patients with successfully resected main duct IPMN (MD-IPMN).These tumors have been referred to by several names over the past few decades, including mucinous duct ectasia, cystic adenocarcinoma, intraductal cystadenocarcinoma, and mucin/mucous hypersecreting tumor, among others. The 1996 World Health Organization classification designated these tumors as intraductal papillary mucinous tumors, 2 and this was revised to IPMN in the 2010 publication. 3 Intraductal papillary mucinous neoplasms result from the intraductal proliferation of mucin-producing neoplastic epithelium, leading to hypercellular outgrowths that secrete frank mucinous fluid.
The incidence of IPMNs has been increasing, in large part owing to increased awareness and the increased use and quality of cross-sectional imaging 4 ; however, the clinical management of IPMNs continues to present challenges. In the past, a more aggressive approach to surgical resection was recommended, mainly owing to fears surrounding the presence of occult malignancies and the potential for malignant transformation. Currently, a more conservative approach is favored based largely on limited retrospective clinical data that may still result in the overtreatment of a large number of patients with these pancreatic neoplasms. The challenge lies in predicting which tumors are high risk and will progress to invasive disease. This review summarizes the pathologic classification of lesions and current management guidelines, and it describes ongoing efforts to more clearly identify IPMNs with malignant potential and ongoing malignant transformation.
PATHOLOGIC CHARACTERIZATION
IPMNs are classified as main duct (MD-IPMN), branch duct (BD-IPMN), or mixed type according to the anatomic involvement of the pancreatic ductal system. Main duct IPMNs have a higher risk of malignant transformation; the risk of malignancy has been found to range from 19% to 30% in BD-IPMNs and as high as 40% to 60% in MD-IPMN. [5] [6] [7] [8] Pancreatic epithelial cells display varying degrees of dysplasia: low-grade dysplasia (previously termed adenoma), moderate dysplasia (previously termed borderline tumor), high-grade dysplasia (previously termed carcinoma in situ), and invasive carcinoma (Fig. 1 ). Although this is thought to follow the adenoma-carcinoma sequence, it is likely that some IPMNs with low-grade dysplasia will not progress to high-grade dysplasia or invasive carcinoma. At the recent Baltimore Consensus Meeting for pancreatic neoplastic precursor lesions, the classification system was changed from a 3-tier to a 2-tier system, with the IPMNs formerly classified as low-grade as well as intermediate-grade, now being classified as low-grade IPMN. 10 Histologically, IPMNs can be classified into 4 subtypes based on morphological and immunohistochemical characteristics: gastric, intestinal, pancreatobiliary, and oncocytic (Table 1) . 11 Although not always the case, gastric type IPMNs typically display low-grade dysplasia, intestinal type IPMNs often display moderate to highgrade dysplasia, whereas the less common pancreatobiliary type and oncocytic type IPMNs often display high-grade dysplasia. The 2 main histopathological types of invasive IPMN are colloid carcinoma, which typically arises from intestinal type IPMN, and tubular carcinoma, which arises from pancreatobiliary type IPMN. Histologic subtypes are typically only determined after surgical resection and currently may not be used to dictate clinical management.
CONSENSUS GUIDELINES AND RECOMMENDATIONS
The management of IPMNs is predicated on the accurate assessment of the risk of malignant transformation. Because definitive diagnosis of malignant transformation is difficult preoperatively, this has been estimated by evaluating the presenting signs and symptoms, in concert with imaging features.
The Sendai international consensus guidelines, published in 2006, recommended resection for all MD-IPMNs and mixed type IPMNs if patients are good surgical candidates. Resection was also recommended for symptomatic patients with BD-IPMNs, or BD-IPMNs with main duct dilatation greater than 6 mm or the presence of mural nodules. It was also recommended that lesions greater than 3 cm be resected, with the caveat that more data were required to determine whether all BD-IPMNs greater than 3 cm should be resected immediately. Follow-up with computed tomography (CT)/magnetic resonance imaging (MRI) was recommended for asymptomatic cystic lesions without main duct dilatation greater than 6 mm, without mural nodules and those less than 3 cm in size, because they have a low risk of progressing to invasive cancer in short term follow-up (12-36 months). Yearly follow-up was recommended for lesions less than 1 cm in size, 6 to 12 monthly follow-up for lesions 1 to 2 cm and 3 to 6 monthly follow-up for lesions greater than 2 cm. 12 These guidelines were revised in 2012, during the Fukuoka consensus meeting (Fig. 2) . 13, 14 Major changes included a decreased threshold of main duct dilatation for characterization of MD-IPMN Both high-risk stigmata and worrisome features were defined, with surgical resection recommended for high-risk stigmata, namely, obstructive jaundice in a patient with a cystic lesion in the head of the pancreas, enhancing mural nodules, and main pancreatic duct diameter of greater than or equal to 10 mm. Worrisome features included cyst size of greater than or equal to 3 cm, thickened or enhancing cyst walls, main duct size of 5 to 9 mm, nonenhancing mural nodules, an abrupt change in pancreatic duct caliber with distal pancreatic atrophy, pancreatitis, and lymphadenopathy. The presence of any of these is an indication for endoscopic ultrasound (EUS). Definite mural nodules or main duct involvement (thickened walls, intraductal mucin, or mural nodules) on EUS or cytology that is suspicious or positive for malignancy remains an indication for surgical resection.
In the absence of worrisome features or high-risk stigmata, follow-up with CT/MRI is recommended every 2 to 3 years for lesion size less than 1 cm and yearly for 2 years with lengthening of interval evaluation if no change in size for lesion size 1 to 2 cm. Recommendations include consideration for surgical resection in young, healthy patients with lesions 2 to 3 cm, and strong consideration of the same for lesions greater than 3 cm. In addition, for lesions 2 to 3 cm, an EUS is recommended in 3 to 6 months, with alternating MRI and EUS at lengthened intervals thereafter and alternating MRI and EUS for surveillance every 3 to 6 months for lesions greater than 3 cm if surgical resection is not performed.
Despite the improvements in the management of IPMNs since the previous guidelines, overtreatment remains a major problem for a large number of these patients. The decision to observe versus proceed with surgical resection is a complex one and requires maintaining a balance between the risk of potential malignancy and the risk of pancreatic resection. Most available data have been derived from retrospective studies with a substantial selection bias. Pancreatic resection for worrisome imaging features often demonstrates pathology consistent with low-grade dysplasia. A recently published multi-institutional study of 324 patients by Wilson et al 15 found that 44% of specimens resected according to current guidelines had only low-grade dysplasia. Other studies have demonstrated similar percentages of low-grade dysplasia in resected specimens. 16 Many studies have evaluated the performance of the Sendai and Fukuoka guidelines.
Single-Institution Studies
Han et al 17 evaluated the utility of the Sendai and Fukuoka consensus guidelines in a retrospective review of 230 patients. Presence of any one of thickened walls, intraductal mucin, or mural nodules is suggestive of main duct involvement. In their absence, main duct involvement is inconclusive. § Studies from Japan suggest that on follow-up of subjects with suspected BD-IPMN there is increased incidence of PDAC unrelated to malignant transformation of the BD-IPMN(s) being followed. However, it is unclear if imaging surveillance can detect early adenocarcinoma and, if so, at what interval surveillance imaging should be performed.
They reported a sensitivity and specificity of 90% and 34% with the Sendai guidelines and 55% and 78% with the Fukuoka guidelines. Likewise, their reported positive predictive values and negative predictive values were 41% and 87% with the Sendai guidelines and 55% and 78% with the Fukuoka guidelines. Jaundice, a main pancreatic duct diameter greater than 10 mm, and abdominal pain were the only independent predictors of malignancy in this study. Mural nodules were not predictive for development of malignancy in this study.
Mural nodules, although included in the Sendai and Fukuoka guidelines, and often reported to be predictive of malignancy, are often not addressed on CT imaging reports. A study by Ridtitid et al 18 report that 28% of mural nodules detected by EUS were missed by CT and MRI. In addition, their study found that the mean size of mural nodules on EUS was associated with malignancy, and in contradistinction to other studies that demonstrate nodule size of greater than 7 to 10 mm being strongly associated with malignancy, [19] [20] [21] their study detected significantly smaller mural nodules in malignant BD-IPMNs, with mean mural nodule size of 3.7 mm in malignant BD-IPMNs. 18 Studies have also examined other radiologic features that are predictive of malignancy in IPMNs. In their recent study, Strauss et al 22 reported common bile duct dilatation and parenchymal atrophy to be the best independent predictors of malignancy in BD-IPMNs.
Shimizu et al 23 developed a nomogram to attempt to predict the probability of the presence of carcinoma in patients with IPMNs. Sex, type of lesion (MD-IPMN vs BD-IPMN), size of mural nodules, and pancreatic fluid cytology were all assigned points, and the value of the total points was assigned a predicted cancer probability. The sensitivity and specificity of this model were reported to be 97.1% and 68.1%, respectively, when a predictive probability of greater than 10% was used to indicate the presence of carcinoma. 23 
Multi-institutional Studies
Kim et al, 24 in a nationwide multicenter study in Korea, reported that cyst size greater than 3 cm, enhancing mural nodules on CT imaging, and mural nodules greater than 5 mm on EUS were independent risk factors for the presence of malignancy in BD-IPMNs. Cyst size greater than 3 cm had a sensitivity of 88% but a relatively low specificity of 52.9%. Sensitivity and specificity were 48.7% and 94.9% for enhancing mural nodules on CT and 84% and 77.7% for mural nodules greater than 5 mm on EUS.
Attiyeh et al 25 developed a nomogram to preoperatively predict IPMN grade of dysplasia in MD-IPMNs and BD-IPMNs: weight loss, presence of symptoms, cyst size, mural nodule with solid component, and main duct diameter greater than 1 cm were the variables included in the MD-IPMN nomogram, whereas age, sex, presence of symptoms, cyst size, and mural nodule with solid component were included in the BD-IPMN nomogram used to predict high risk disease. This was studied in both training and validation cohorts with C-indices of 0.82 and 0.81, respectively. 25 
Systematic Reviews and Meta-analyses
Goh et al 26 reviewed the literature for studies evaluating the utility of the Sendai consensus guidelines. They evaluated 12 studies with a pooled sample size of 690 resected BD-IPMNs and found that, although the negative predictive values of the applied guidelines ranged from 90% to 100%, the positive predictive values ranged from 11% to 52%. 26 Anand et al 27 performed a meta-analysis that examined 41 studies and reported that cyst size greater than 3 cm, presence of a mural nodule, dilation of main pancreatic duct, and MD-IPMN were predictive of malignancy, with cyst size greater than 3 cm being the most strongly associated with malignancy. 27 Sultana et al 28 examined 37 studies and reported pooled sensitivities and specificities of risk factors predictive of malignancy of 80% and 76% for CT/MRI but 96% and 91% for PET imaging. The presence of a mural nodule on imaging was the most sensitive variable in this study. 28 
Other Studies
The neutrophil to lymphocyte ratio is an inflammatory marker that has been correlated with poor survival in patients with pancreatic cancer and other solid tumors. 29 Gemenetzis et al 30 demonstrated that an elevated neutrophil to lymphocyte ratio greater than 4 was significantly associated with IPMN-associated invasive carcinoma (P < 0.001). Additional significant variables were cyst size greater than 3 cm (P < 0.001), main pancreatic duct dilatation greater than 5 mm (P < 0.001), and jaundice (P < 0.001). Although the developed predictive model using these variables had a C-index of 0.895, this study only evaluated IPMN-associated invasive carcinoma versus noninvasive carcinoma, and the latter group did contain IPMNs with highgrade dysplasia. 30 
FUTURE DIRECTIONS Molecular Investigations
In addition to the clinical and radiological studies, attention has also turned to the search for molecular markers to help us better understand the progression from IPMNs with low-grade dysplasia to invasive carcinoma (Table 2 ). An early study by Nishihara et al 41 
DNA-Based Biomarkers
Fukuda et al 32 demonstrated that Brg1 null IPMN-pancreatic ductal adenocarcinoma (PDAC) was less lethal than pancreatic intraepithelial neoplasia (Pan-IN)-derived PDAC that is driven by mutant Kras and hemizygous p53 deletion. Transgenic mice with Brg1 deletion developed spontaneous cystic pancreatic neoplasms that closely resembled pancreatobiliary type IPMNs that then progressed to IPMN-derived PDAC. In addition, other genes such as Mmp7, Gabrp, Hmga2, Clic3, and Adams1 previously shown to be involved in Pan-IN derived PDAC were downregulated in IPMN-PDACs. 32 Hong et al 42 in a 2011 publication reviewed studies that characterized the molecular signatures of pancreatic cancer and demonstrated that activating point mutations of KRAS are present in approximately 50% of IPMNs with low-grade dysplasia, but the prevalence of KRAS mutations did increase with the degree of dysplasia. In addition, inactivating CDKN2A and p53 mutations were found in IPMNs with high-grade dysplasia, as were aberrant methylation patterns. 42 KRAS mutations were also found to be more prevalent in invasive IPMNs than in premalignant IPMNs in some other studies, 43 but there are other studies in which this was not found to be the case.
44,45
Pancreas
IPMN, Stratification of Malignancy Risk
In a 2015 study evaluating mutations in pancreatic cancer and associated precursor lesions, Hosoda et al 33 found frequent GNAS mutations in IPMNs as well as other pancreatic mucinous tumors, both with and without associated adenocarcinomas. In addition, although mucinous IPMN associated adenocarcinomas were associated with a high prevalence of GNAS mutations, tubular type adenocarcinomas were more heterogeneous. This study did not find a difference in GNAS mutation patterns between IPMNs with and without associated adenocarcinoma. 33 Whole exome sequencing also revealed frequent GNAS mutations in IPMNs, but not in PDACs. 46 Kuboki et al 34 evaluated molecular biomarkers to assess their association with the progression of dysplasia in IPMNs. Their study demonstrated that both GNAS and KRAS mutations were present in approximately half of IPMNs. GNAS mutations were associated with intestinal type IPMNs, whereas KRAS mutations were associated with gastric and pancreatobiliary type IPMNs. Increased EGFR expression was associated with higher histological grade, as were increased expressions of AKT and p53 and loss of SMAD4. MAPK expression was more commonly observed in low-grade dysplasia. No EGFR mutation, loss of SMAD4, or p53 overexpression was seen in any IPMNs with low-grade dysplasia. 34 Abnormal P53 protein accumulation was also found to be more frequent in high-grade dysplasia and carcinoma compared with adenomas in the study by Mohri et al 45 ; however, the reduction of SMAD4 expression did not correlate.
Lee et al 35 performed a meta-analysis to evaluate the incidence of KRAS, GNAS, and RNF43 mutations in IPMNs. Although their pooled analysis did demonstrate a different mutational profile that was significantly related to the histologic subtype, they did not demonstrate any such association with the presence of adenocarcinoma in IPMNs. 35 Nissim et al 36 performed a meta-analysis of 39 studies to determine the relationship between various genetic alterations and malignant transformation in IPMNs and determined that expression of hTERT (the human telomerase reverse transcriptase gene that encodes the catalytic component of telomerase required to overcome telomere shortening and cellular senescence) and Shh (the secreted factor sonic hedgehog which plays an important role in regulating normal pancreas development) was strongly associated with malignant transformation with odds ratios of 11.4 (95% confidence interval [CI], 3.5-36.7) and 6.9 (95% CI, 2.4-20.2), respectively. 36 In the study by Durante et al, 37 high-resolution cytogenetic analysis was performed using formalin-fixed paraffin-embedded samples. Intraductal papillary mucinous neoplasms with lowintermediate grade dysplasia were found to have a nearly normal karyotype with either no copy number alterations or only 1 focal gain, whereas IPMNs with high-grade dysplasia had a complex karyotype with greater than 4 macroscopic copy number gains/ losses and 10 copy number alterations each on average. In addition, a specific gain of chromosome arm 3q encompassing the PIK3CA, GATA2, and TERC oncogenes was detected in 92% of IPMNs with a complex karyotype. miRNA expression revealed a corresponding upregulation of PIK3CA (4-fold) and TERC (2-fold) in these IPMNs, whereas GATA2 was not upregulated.
Wu et al, 38 in a whole exome sequencing of pancreatic cystic neoplasms, demonstrated that the most commonly mutated gene in IPMNs was RNF43, located on chromosome 17q, with this mutation found in 6 out of 8 IPMNs. This gene was also noted to be deleted in mucinous cystic neoplasms. 38 
Cyst Fluid Analysis
Cyst fluid analysis is being studied so as to evaluate potential candidate biomarkers that may be used to preoperatively, in a complementary fashion with clinical and radiological features, to differentiate between high-grade and low-grade IPMNs. Wu et al 47 also evaluated pancreatic cyst fluid and noted KRAS or GNAS mutations in 96% of 19 samples (KRAS mutation in 14 and GNAS mutations in 6 IPMNs, respectively, with both mutations Single-institution study: pancreatic cyst fluid analysis from 91 pancreatic cysts, followed by surgical resection GNAS and KRAS mutations have a 100% specificity and 65% sensitivity for mucinous tumors FFPE indicates formalin-fixed paraffin embedded.
seen in more than half). The same mutations were noted in the cyst wall as well as the cyst fluid, thus confirming that cyst fluid mutations provide an accurate representation of neoplastic cells in the IPMN. However, neither of these mutations were able to distinguish highgrade lesions from low-grade lesions. 47 Nikiforova et al 39 tested pancreatic cystic fluid obtained at the time of EUS for KRAS mutations and noted that KRAS mutations had a specificity of 100% but a sensitivity of 54% for mucinous differentiation (67% for IPMNs and 14% for mucinous cystic neoplasms). However, their study noted that 53% of specimens were suboptimal or unsatisfactory for analysis. 39 Singhi et al 40 describe GNAS and KRAS testing on pancreatic cyst fluid obtained from EUS as part of routine clinical evaluation. GNAS mutations were detected in 30% of IPMNs and 22% of IPMNs with adenocarcinoma, KRAS mutations were detected in 68% of IPMNs and 78% of IPMNs with adenocarcinoma, and mutations in either gene were detected in 83% of IPMNs and 89% of IPMNs with adenocarcinoma. GNAS and KRAS mutations had 100% specificity and 65% sensitivity for mucinous differentiation. 40 
miRNA-Based Biomarkers
Distinct miRNA profiles are also found to be associated with the malignant transformation of pancreatic cystic neoplasms (Table 3) . miRNAs are excellent candidate biomarkers owing to their tissue specific expression, stability in biofluids, and involvement in several biological pathways. 52 In a study by Frampton et al, 48 upregulation of miR-21, miR-155, and miR-708 was demonstrated to be associated with the malignant transformation of IPMNs.
In a multicenter study, Caponi et al 49 evaluated 3 specific candidate miRNAs that were selected based on prior studies: miR-21, miR-155, and miR-101 as potential biomarkers in IPMNs and demonstrated that miR-21 and miR-155 were upregulated in invasive IPMNs compared with noninvasive IPMNs and in noninvasive IPMNs compared with normal tissue. miR-101 levels were upregulated in noninvasive IPMNs and normal tissues compared with invasive IPMNs. miR-21 was found to be an independent prognostic factor for mortality and disease progression. 49 Matthaei et al 50 identified 18 candidate miRNAs that separated high-grade IPMNs from low-grade IPMNs using cyst fluid analysis and developed a logistic regression model using 9 miRNAs to separate high-grade IPMNs from low-grade IPMNs with 89% sensitivity and 100% specificity. The most important miRNAs in the regression model included miR-24, miR-30a-3p, miR-18a, miR-92a, and miR-342-3p. Other miRNAs in the model included miR-99b, miR-106b, miR-142-3a, and miR-532-3p. 50 Wang et al 51 also performed exploratory next-generation sequencing-based profiling of miRNAs in cyst fluid and determined that 13 miRNAs were enriched (miR-138, miR-195, miR-204, miR-216a, miR-217, miR-218, miR-802, miR-155, miR-214, miR-26a, miR-30b, miR-31, miR-125), and 2 miRNAs (miR-451a, miR-4284) were depleted in cyst fluid from high-grade and invasive IPMNs compared with low-grade IPMNs. 51 Of note, 5 of these miRNAs were also reported in the prior miRNA profiling study by Matthaei et al, 50 although they were not included in the published regression model.
Quantitative Imaging
Diffusion weighted imaging, a technique of magnetic resonance imaging that is based upon measuring the random Brownian motion of water molecules within a voxel of tissue, has been used for the detection and characterization of a number of types of tumors. Kim et al, 53 in a retrospective study of 132 patients, evaluated diffusion restriction as well as the imaging parameters of high-risk stigmata and worrisome features based on the Fukuoka consensus guidelines. They reported that the presence of diffusion restriction in IPMNs was the only independent imaging parameter for prediction of malignancy and invasiveness, with a diagnostic accuracy that was significantly improved compared with using only the high-risk stigmata. 53 Radiomics is the high-throughput extraction and analysis of large amounts of quantitative image features from radiographic studies to attempt to capture additional information from these images. It is a rapidly expanding field and has been used for the detection of prostate cancer, renal cell carcinoma, non-small-cell lung cancer, and other cancers. Radiomics is based on the hypothesis that genomic and proteomic patterns may be expressed as macroscopic image-based features. It involves analyzing highquality standardized imaging, defining the tumor either by an experienced reviewer or, more recently, by the use of automated segmentation methods, and then extracting quantitative imaging features from the tumor and surrounding tissues of interest. Features analyzed include tumor signal intensity, shape characterization, texture heterogeneity patterns, and the relationship of the tumor with surrounding tissues. Hanania et al 9 evaluated 53 cases of IPMN (34 high grade and 19 low grade) and quantitatively analyzed the cysts and pancreatic parenchyma to differentiate high-grade lesions from low-grade lesions using 14 imaging biomarkers (all within the Gray Level CoOccurrence Matrix). A cross validated panel created using 10 of these markers yielded an area under the curve (AUC) of 0.96 (95% CI, 0.92-0.99), at a sensitivity of 97% and specificity of 88%.
Permuth et al 54 combined both radiomic features and a miRNA genomic classifier data to differentiate malignant from benign IPMNs with a sensitivity of 83% and specificity of 89% (AUC,0.92). These authors had previously performed a genome wide miRNA analysis and had demonstrated a 5 miRNA genomic classifier (miR-200a-3p, miR-1185-5p, miR-33a-5p, miR-574-4p, and miR-664b) that could discriminate between malignant (highgrade dysplasia or invasive) and benign IPMNs with an AUC of 0.73. These miRNAs are thought to have a tumor suppressor role, because expression was noted to be 2-to 3-fold lower in malignant IPMNs compared with benign IPMNs. 55, 56 Their current study revealed 14 radiomic features: 11 textural and 3 nontextural features (size and shape) that were used in combination with the miRNA genomic classifier to more accurately differentiate malignant from benign IPMNs. 54 A major hurdle for this approach will be to address the heterogeneous nature of radiomic data, largely owing to the nonstandardization of imaging protocols and imaging machines across multiple institutions. This is thought to be the reason that studies performed at a single institution are difficult to reproduce elsewhere. This challenge is being actively studied to develop standardized protocols by various teams including our own, as part of the Molecular and Cellular Characterization Laboratory Consortium for Overdiagnosis, supported by the National Institute of Health.
CONCLUSIONS
Although we have gained much our understanding of the molecular drivers and clinical behavior of IPMNs over the past decade, the management of IPMNs is still particularly challenging. The natural history of the disease and the events that permit progression to adenocarcinoma are still not entirely understood, highlighting the urgent need for a genetically engineered animal model of the disease. It is clear that IPMNs with high-grade dysplasia are high-risk lesions that will likely transform into invasive carcinoma and should be treated with surgical resection in appropriate patients. Although large cyst size, enhancing mural nodules, and clinical symptoms such as jaundice are worrisome findings and should result in surgical resection, smaller tumors are also noted to have high-grade dysplasia or invasive carcinoma when resected. The Sendai and Fukuoka guidelines help establish a working model for treatment. However, given the existing guidelines, there is evidence that physicians are still overtreating a large number of patients.
Genetic characterization of the disease has helped guide development of molecular panels of genes associated with disease progression. This approach is limited owing to the use of surgically resected tissues, which is not helpful in differentiating between high-grade IPMNs and low-grade IPMNs preoperatively. Pancreatic cyst fluid analysis is a developing field of study with tremendous clinical potential, and the identification of biomarkers that may be differentially expressed in low versus high-grade IPMNs will help to identify patients who will most benefit from surgery. Studies in the field of radiomics and imaging characteristics of pancreatic tumors, although still in the very early stages, have shown promise.
Clinical decision-making in the treatment of IPMNs needs to be individualized for each patient, given their age, tumor appearance on radiologic imaging and EUS, and other risk factors, especially given the morbidity and mortality associated with the surgical procedures often required. Emerging technologies that provide us with additional ways to help differentiate low from high-grade IPMNs preoperatively should be evaluated in multi-institutional studies to enable us to more accurately risk stratify patients who will benefit from surgical resection. In addition, large multi-institutional studies are also necessary to help us continue to understand the progression of this disease, the burden of overtreatment, and its involved costs and possible complications.
